Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 187

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 187
---
 trial in SCLC and NETs where there is a significant need for new treatment options. We plan to
complete IND-enabling studies, linker-payload process development and submit an IND in mid-2026.

- 130 -

MATTERS FOR APPROVAL AT THE SPECIAL MEETING

PROPOSAL NO. 1:

APPROVAL OF THE DIVESTITURE PROPOSAL

THE AADI BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT AADI STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THE DIVESTITURE AND THE
TRANSACTIONS CONTEMPLATED BY THE DIVESTITURE AGREEMENT.

Overview

The Divestiture is the sale by Aadi to Kaken of 100% of the outstanding shares of capital stock of Aadi Sub and thereby all or substantially all of Aadi’s
assets related to its FYARRO Business, pursuant to the terms of the Divestiture Agreement, which may be deemed to be a sale of substantially all of Aadi’s assets under Section 271 of the DGCL. We are seeking the approval of Aadi
stockholders for the Divestiture because the question of whether the Divestiture constitutes the sale of substantially all of the assets of Aadi under the DGCL is highly fact-specific, and because Aadi’s board of directors considered the action
appropriate and strongly desire the input of Aadi stockholders, given the financial significance of the FYARRO Business.

The transaction is expected to
close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Upon the closing of this transaction, Kaken will also acquire the rights to the Aadi name and trademark.

Aadi’s board of directors has determined that the Divestiture is advisable and in the best interests of Aadi, and has approved the Divestiture Agreement
and the Divestiture. A copy of the Divestiture Agreement is attached as Annex A to this proxy statement and incorporated herein by reference. Aadi stockholders are urged to carefully read the Divestiture Agreement in its entirety.

Consequences if the Divestiture Proposal is Not Approved

If the Aadi stockholders do not approve the Divestiture Proposal, the Divestiture will not be completed. If the Divestiture is not completed, the Divestiture
Agreement provides that, upon termination of the Divestiture Agreement under certain circumstances, Aadi may be required to pay to Kaken a termination